VIVANI MED.INC. NEW O.N. Cash Flow Conversion Efficiency
VIVANI MED.INC. NEW O.N. cash flow conversion efficiency. Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has a cash flow conversion efficiency ratio of -0.427x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.72 Million ≈ $-7.86 Million USD) by net assets (€15.73 Million ≈ $18.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of VIVANI MED.INC. NEW O.N. (2021–2025)
Cash flow conversion efficiency of VIVANI MED.INC. NEW O.N. from 2021 to 2025. This chart illustrates how VIVANI MED.INC. NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of VIVANI MED.INC. NEW O.N. for real-time trading data and today's change.
VIVANI MED.INC. NEW O.N. Cash Flow Conversion Ratio Explained
VIVANI MED.INC. NEW O.N. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
VIVANI MED.INC. NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their cash flow conversion efficiency. Also see VIVANI MED.INC. NEW O.N. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vera Bradley Inc
NASDAQ:VRA
|
-0.042x |
|
GeeCee Ventures Limited
NSE:GEECEE
|
0.109x |
|
Dongyang E&P Inc
KQ:079960
|
0.037x |
|
Alcadon Group AB
ST:ALCA
|
0.063x |
|
Delta Djakarta Tbk
JK:DLTA
|
0.097x |
|
Havila Kystruten AS
OL:HKY
|
-0.034x |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
-0.089x |
|
Cufe Ltd
AU:CUF
|
-0.110x |
Annual Cash Flow Conversion Efficiency for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of VIVANI MED.INC. NEW O.N. from 2021 to 2025. Review how financially flexible is VIVANI MED.INC. NEW O.N. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.73 Million ≈ $18.39 Million |
€-24.32 Million ≈ $-28.43 Million |
-1.546x | -30.99% |
| 2024-12-31 | €17.61 Million ≈ $20.59 Million |
€-20.79 Million ≈ $-24.30 Million |
-1.180x | -3.40% |
| 2023-12-31 | €20.76 Million ≈ $24.27 Million |
€-23.70 Million ≈ $-27.71 Million |
-1.142x | -169.22% |
| 2022-12-31 | €44.31 Million ≈ $51.80 Million |
€-18.79 Million ≈ $-21.96 Million |
-0.424x | +90.46% |
| 2021-12-31 | €2.46 Million ≈ $2.88 Million |
€-10.95 Million ≈ $-12.80 Million |
-4.443x | -- |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more